Aglaia Oncology Fund

VCMatch tracks Aglaia Oncology Fund as an investor focused on Biotech and Pharma companies and Pre-Seed and Seed rounds. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Pre-Seed, Seed, Series A

Focus Areas

Biotech, Pharma

Geography

Not specified

Investment Thesis

Aglaia focuses on backing and actively maturing early-stage oncology drug development programs. The firm emphasizes hands-on, operational involvement — working “in close collaboration with innovators and entrepreneurs” and bringing experience in designing R&D plans “ranging from early screening and animal feasibility studies through clinical studies” — with the explicit aim of de-risking and maturing assets until they become “attractive candidates for licensing, acquisition or IPO.”

Is Aglaia Oncology Fund right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Aglaia Oncology Fund is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech and Pharma.

Focus statement

Aglaia "invests in oncology drug development companies," primarily at early stages, targeting "breakthrough inventions that have the potential to transform cancer treatment."

Value Add

Deep sector focus: exclusively oncology drug development (repeatedly stated as "Aglaia invests in oncology drug development companies").
Proven track record of company creation and maturation: "Aglaia has invested in 12 early stage companies, of which 6 were founded by Aglaia."
Extensive hands-on operational capabilities: team involvement across discovery to clinical development and in defining strategic directions for portfolio companies.
Experienced team: decades of cancer research and drug development experience and involvement in development of "more than 100 oncology products."
Impact measurement capability: co-creation of the Life Sciences Impact Suite (50 impact indicators across Science & Innovation, Clinical, Socio-Economical, and Financial themes) to assess socio-economic impact of investments.
Continuous strategic and operational involvement that emphasizes transitioning early-stage companies to clinical-stage (explicitly framed as a key contributor to their success rate).